Robert's Feed
Nov 6, 2015
via Breakingviews

Valeant CEO gets called on $100 mln excess

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Valeant Pharmaceuticals Chief Executive Mike Pearson has been called on his $100 million excess. That’s how much stock he put in hock to do everything from paying taxes to donating to charity to buying more shares in the company – he even helped finance a community swimming pool.

Nov 6, 2015
via Breakingviews

Job data rarely work as gauge of economy’s health

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Wall Street’s obsession with monthly employment figures is nuts. The 271,000 U.S. jobs created in October are obviously important for those who found work, but the number means less than investors might think. Nonfarm payroll data are volatile, prone to revision and lousy indicators of economic health. They’re important mostly because traders, analysts and journalists give them outsized attention.

Nov 5, 2015
via Breakingviews

Bill Ackman pushes limits of activism at Valeant

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Bill Ackman is pushing the limits of activism at Valeant Pharmaceuticals. The $55 billion of quickly lost market value, including some $4 billion more on Thursday, suggests his involvement isn’t helping.

Nov 5, 2015
via Breakingviews

Bill Ackman pushes limits of activism at Valeant

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Bill Ackman is pushing the limits of activism at Valeant Pharmaceuticals. The $55 billion of quickly lost market value, including some $4 billion more on Thursday, suggests his involvement isn’t helping.

Nov 5, 2015
via Breakingviews

Bill Ackman pushes limits of activism at Valeant

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Bill Ackman is pushing the limits of activism at Valeant Pharmaceuticals. The $55 billion of quickly lost market value, including some $4 billion more on Thursday, suggests his involvement isn’t helping.

Oct 30, 2015
via Breakingviews

Ackman’s Valeant defense nervy but unpersuasive

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Hedge fund founder Bill Ackman’s defense of Valeant Pharmaceuticals was nervy but unpersuasive. The Pershing Square Capital boss says the $34 billion drug giant is a victim of bad public relations, naive investors and jealous rivals. He even likened his stake to one of Berkshire Hathaway chief Warren Buffett’s riskiest but most successful bets. The reality is the company is flawed in ways that Ackman’s “pep talk” won’t fix.

Oct 30, 2015
via Breakingviews

Ackman’s Valeant defense nervy but unpersuasive

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Hedge fund founder Bill Ackman’s defense of Valeant Pharmaceuticals was nervy but unpersuasive. The Pershing Square Capital boss says the $34 billion drug giant is a victim of bad public relations, naive investors and jealous rivals. He even likened his stake to one of Berkshire Hathaway chief Warren Buffett’s riskiest but most successful bets. The reality is the company is flawed in ways that Ackman’s “pep talk” won’t fix.

Oct 29, 2015
via Breakingviews

Pfizer may overdose on quick and complex deals

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Pfizer may be about to overdose on quick and complex deals. The drug giant is in talks to buy $120 billion rival Allergan and seems likely to split the merged firm. It’s moving briskly to take advantage of low share prices and tax benefits that could vanish with a new Congress. Speed can prompt missteps, though, as Pfizer knows only too well.

Oct 29, 2015
via Breakingviews

Pfizer may overdose on quick and complex deals

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Pfizer may be about to overdose on quick and complex deals. The drug giant is in talks to buy $120 billion rival Allergan and seems likely to split the merged firm. It’s moving briskly to take advantage of low share prices and tax benefits that could vanish with a new Congress. Speed can prompt missteps, though, as Pfizer knows only too well.

Oct 28, 2015
via Breakingviews

No simple cures for Gilead and Apple valuations

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

There are no simple cures for the valuations of Gilead Sciences and Apple. Like the $670 billion iPhone maker, the $158 billion biotech is the leader in its industry and churns out hefty profit. Yet its stock trades at a big price-to-earnings discount to the broader market. Investor impatience for astonishing new products – and fears that neither company will find them – borders on the irrational.

    • About Robert

      "Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the start-up of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University."
    • Follow Robert